GlassScriptPhysician profile
Leah Atkinson
NPI 1043548357
$2,336.07
in general payments reported to CMS, 2019-2025
21 companies · $799 in 2025
The $799 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $89.88 · 2022: $200 · 2023: $498 · 2024: $749 · 2025: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,947 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,947.21 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $354.51 | 2023-2025 | Opdivo, Reblozyl, Opdualag |
| Celgene Corporation | $341.74 | 2021-2025 | Reblozyl, Pomalyst, Opdivo |
| Novartis Pharmaceuticals Corporation | $306.33 | 2021-2025 | |
| Pfizer INC. | $189.91 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $185.31 | 2023-2024 | Keytruda |
| Takeda Pharmaceuticals U.S.A., INC. | $184.57 | 2022-2024 | |
| Abbvie INC. | $176.17 | 2024-2025 | |
| Kite Pharma, INC. | $138.86 | 2023 | Yescarta |
| Incyte Corporation | $99.00 | 2025 | |
| Beigene USA, INC. | $75.16 | 2022-2024 | Brukinsa |
| Jazz Pharmaceuticals INC. | $54.13 | 2021 | |
| Astellas Pharma US INC | $33.14 | 2025 | Xtandi |
| Janssen Biotech, INC. | $29.31 | 2022-2025 | Erleada |
| Amgen INC. | $29.18 | 2022-2023 | Lumakras |
| Springworks Therapeutics, INC. | $25.14 | 2024 | Ogsiveo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $22.20 | 2024 | Lunsumio |
| Tempus Ai, INC | $20.57 | 2025 | Xt Cdx |
| Gilead Sciences, INC. | $19.19 | 2025 | Trodelvy |
| Daiichi Sankyo INC. | $18.25 | 2024 | Enhertu |
| Array Biopharma INC | $17.49 | 2024 | Xalkori, Lorbrena, Braftovi |
| Aveo Pharmaceuticals, INC. | $15.91 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leah Atkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.